Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 521
- Registration Number
- NCT00005047
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States
🇺🇸William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-05-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00024050
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 1086
- Registration Number
- NCT00022516
- Locations
- 🇦🇺
Christchurch Hospital, Christchurch, Australia
🇧🇪CHU Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium
🇮🇹Ospedale Sant' Eugenio, Rome, Italy
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027547
- Locations
- 🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
🇩🇪Universitaet Leipzig, Leipzig, Germany
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00027573
- Locations
- 🇺🇸
CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Oklahoma, Tulsa, Oklahoma, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- German Hodgkin's Lymphoma Study Group
- Target Recruit Count
- 220
- Registration Number
- NCT00025636
- Locations
- 🇧🇪
Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
🇩🇪Universitaetsklinikum Essen, Essen, Germany
🇩🇪Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 79
- Registration Number
- NCT00020943
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 393
- Registration Number
- NCT00004228
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3054
- Registration Number
- NCT00005945
- Locations
- 🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00003273
- Locations
- 🇺🇸
Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States
🇺🇸Maine Children's Cancer Program, Scarborough, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.